Spots Global Cancer Trial Database for kras
Every month we try and update this database with for kras cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy | NCT02957266 | Cervical Cancer | Volumetric Arc ... Interstitial br... Cisplatin Gemcitabine PIK3CA KRAS BRAF RRM1 | 18 Years - 70 Years | The National Center of Oncology, Azerbaijan | |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | NCT05737706 | Solid Tumor Advanced Solid ... Non-small Cell ... Colo-rectal Can... Pancreatic Aden... | MRTX1133 | 18 Years - | Mirati Therapeutics Inc. | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS) | NCT02810262 | Bone Metastases Lung Cancer | Bone metastases... | 18 Years - | Hospices Civils de Lyon | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140 | Colorectal Neop... | Gene mutations ... | 18 Years - | Istituto Clinico Humanitas | |
| CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | NCT01202409 | Gastrointestina... | Panitumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | NCT03190941 | Pancreatic Canc... Gastric Cancer Gastrointestina... Colon Cancer Rectal Cancer | Cyclophosphamid... Fludarabine Anti-KRAS G12V ... Aldesleukin | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | NCT05315180 | Malignant Neopl... Metastatic Canc... | BPI-421286 | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer | NCT01032291 | Colorectal Canc... | cetuximab lenalidomide | 18 Years - | Celgene | |
| Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | NCT04249843 | Solid Tumor B-Raf Mutation-... | BGB-3245 | 18 Years - | MapKure, LLC | |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | NCT03597581 | Gastrointestina... Gastrointestina... Colorectal Canc... Colorectal Neop... Colorectal Carc... Gastric Cancer Gastric Neoplas... KRAS Mutation-R... CRC Colorectal Canc... | ompenaclid FOLFIRI Bevacizumab FOLFOX regimen | 18 Years - | Inspirna, Inc. | |
| Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer | NCT00950820 | Colorectal Neop... | Oxaliplatin, Ca... Oxaliplatin, Ca... | 18 Years - | AIO-Studien-gGmbH | |
| A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | NCT05163028 | Non Small Cell ... Colorectal Canc... Pancreatic Canc... Solid Tumor Cancer Cancer of Pancr... Cancer of Colon | HBI-2376 | 18 Years - | HUYABIO International, LLC. | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | NCT01192165 | Cancer | Trametinib (GSK... Docetaxel Erlotinib Pemetrexed Carboplatin nab-Paclitaxel Cisplatin | 18 Years - | GlaxoSmithKline | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | NCT03745326 | Gastrointestina... Pancreatic Canc... Gastric Cancer Colon Cancer Rectal Cancer | Cyclophosphamid... Fludarabine Aldesleukin anti-KRAS G12D ... | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer | NCT01443377 | Rectal Cancer | Panitumumab | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | NCT00813605 | Metastatic Colo... | FOLFIRI AMG 655 Placebo AMG 479 | 18 Years - | NantCell, Inc. | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | NCT05379985 | Non-small Cell ... Colorectal Canc... Pancreatic Duct... Advanced Solid ... | RMC-6236 | 18 Years - | Revolution Medicines, Inc. | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS) | NCT02810262 | Bone Metastases Lung Cancer | Bone metastases... | 18 Years - | Hospices Civils de Lyon | |
| Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. | NCT01068132 | Colorectal Canc... | Cetuximab FOLFIRI | 18 Years - 80 Years | Regione Lombardia | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | NCT06072781 | Low Grade Serou... | avutometinib Defactinib Pegylated lipos... Paclitaxel Topotecan Letrozole Anastrozole | 18 Years - | Verastem, Inc. | |
| Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | NCT06105021 | Pancreatic Duct... Non-Small Cell ... Colorectal Canc... Solid Tumor KRAS G12V | AFNT-211 | 18 Years - | Affini-T Therapeutics, Inc. | |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | NCT05887492 | Non Small Cell ... Solid Tumors, A... Endometrial Can... Pancreatic Canc... Cervical Cancer Breast Cancer Carcinoma of Un... | TNG260 Pembrolizumab | 18 Years - | Tango Therapeutics, Inc. | |
| A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | NCT05578092 | Solid Tumor Advanced Solid ... Non Small Cell ... Colo-rectal Can... | MRTX0902 MRTX849 | 18 Years - | Mirati Therapeutics Inc. | |
| Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | NCT04146298 | Pancreatic Canc... Pancreatic Neop... Pancreatic Duct... Advanced Cancer | Cyclophosphamid... Fludarabine Mutant KRAS G12... Anti-PD-1 monoc... | 18 Years - 75 Years | Changhai Hospital | |
| First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer | NCT01038037 | Non Small Cell ... | Carboplatin Vinorelbine panitumumab | 18 Years - | Vejle Hospital | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| Cetuximab for Elderly Patients With mCRC | NCT01718808 | Metastatic Colo... | Cetuximab Capecitabine | 70 Years - | Swiss Group for Clinical Cancer Research | |
| A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers | NCT06194877 | Colorectal Canc... Pancreatic Duct... Advanced or Met... | BGB-3245 Panitumumab | 18 Years - | MapKure, LLC | |
| Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | NCT01479465 | Colorectal Canc... | Simtuzumab Placebo to matc... Leucovorin Irinotecan Fluorouracil | 18 Years - | Gilead Sciences | |
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | NCT04620330 | Non Small Cell ... KRAS Activating... | avutometinib (V... avutometinib (V... | 18 Years - | Verastem, Inc. | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | NCT02278133 | Metastatic Colo... | WNT974 LGX818 Cetuximab | 18 Years - | Array BioPharma | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | NCT04620330 | Non Small Cell ... KRAS Activating... | avutometinib (V... avutometinib (V... | 18 Years - | Verastem, Inc. | |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | NCT05315180 | Malignant Neopl... Metastatic Canc... | BPI-421286 | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | NCT04146298 | Pancreatic Canc... Pancreatic Neop... Pancreatic Duct... Advanced Cancer | Cyclophosphamid... Fludarabine Mutant KRAS G12... Anti-PD-1 monoc... | 18 Years - 75 Years | Changhai Hospital | |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | NCT05737706 | Solid Tumor Advanced Solid ... Non-small Cell ... Colo-rectal Can... Pancreatic Aden... | MRTX1133 | 18 Years - | Mirati Therapeutics Inc. | |
| QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | NCT00813605 | Metastatic Colo... | FOLFIRI AMG 655 Placebo AMG 479 | 18 Years - | NantCell, Inc. | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | NCT02538627 | Colorectal Canc... Non-small Cell ... Squamous Cell C... | MM-151 MM-121 MM-141 trametinib | 18 Years - | Merrimack Pharmaceuticals | |
| A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | NCT01925274 | Metastatic Colo... | PF-05212384 irinotecan Cetuximab Irinotecan | 18 Years - | Pfizer | |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | NCT05887492 | Non Small Cell ... Solid Tumors, A... Endometrial Can... Pancreatic Canc... Cervical Cancer Breast Cancer Carcinoma of Un... | TNG260 Pembrolizumab | 18 Years - | Tango Therapeutics, Inc. | |
| A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | NCT01562899 | Metastatic Panc... BRAF Mutated Me... | MEK162 AMG 479 | 18 Years - | Pfizer | |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | NCT02278133 | Metastatic Colo... | WNT974 LGX818 Cetuximab | 18 Years - | Array BioPharma | |
| Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | NCT02906059 | Metastatic Colo... | AZD1775 Irinotecan | 18 Years - | NYU Langone Health | |
| Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer | NCT05068752 | Pancreas Cancer | Vemurafenib Sorafenib | 18 Years - 100 Years | HonorHealth Research Institute | |
| A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | NCT03637491 | Pancreatic Canc... | Avelumab Binimetinib Talazoparib | 18 Years - | Pfizer | |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT04699188 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Colo... Cancer of Lung Cancer of the L... Lung Cancer Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... | JDQ443 TNO155 tislelizumab | 18 Years - | Novartis | |
| A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | NCT05163028 | Non Small Cell ... Colorectal Canc... Pancreatic Canc... Solid Tumor Cancer Cancer of Pancr... Cancer of Colon | HBI-2376 | 18 Years - | HUYABIO International, LLC. | |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140 | Colorectal Neop... | Gene mutations ... | 18 Years - | Istituto Clinico Humanitas | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
